Dr. Michael A. Luther Joins Transgenomic's Board of Directors
March 19 2014 - 7:00AM
Business Wire
Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology
company advancing personalized medicine in cardiology, oncology,
and inherited diseases through diagnostic tests as well as clinical
and research services, today announced the appointment of Michael
A. Luther, Ph.D., to its Board of Directors. Dr. Luther will also
become a member of the Board’s audit committee. His appointment
became effective March 13, 2014.
“Dr. Luther brings a unique combination of scientific expertise,
practical business experience, and effective leadership, and we are
honored to welcome him to the Transgenomic Board,” said Rodney S.
Markin, M.D., Ph.D., Chairman of Transgenomic. “We believe
Michael’s contributions will be invaluable as we continue to
implement our strategic growth initiatives and advance our
molecular diagnostic tests in the personalized medicine
marketplace.”
“I am excited to join the Transgenomic Board during this period
of strategic transformation,” said Dr. Luther. “Molecular
diagnostics will play an integral role in the future of healthcare
and Transgenomic is well-positioned to become a leader in
personalized medicine. The Company has cutting-edge technology
platforms, deep technical expertise, and an excellent management
team. I look forward to working with the entire team and playing a
role in the advancement of its portfolio of medically important
genetic tests.”
Dr. Luther brings over 25 years of business experience to
Transgenomic. He currently serves as Senior Vice President of
Discovery and Development at Albany Molecular Research, Inc.
(AMRI), a publicly-traded, global pharma services organization that
provides discovery, development, and manufacturing to the
biopharmaceutical industry. Dr. Luther joined AMRI from Charles
River Laboratories where he served as Corporate Vice President of
Global Discovery Research Services. Before joining Charles River
Laboratories, he was President and a member of the Board of
Directors of the David H. Murdock Research Institute. Previously,
he held executive and managerial positions at Merck and
GlaxoSmithkline.
Dr. Luther earned his Ph.D. in biochemistry from the St. Louis
University School of Medicine; an M.B.A. from Duke University,
Fuqua School of Business; and a B.Sc. in biology and chemistry from
North Carolina State University. Dr. Luther has authored numerous
scientific papers and has served on Boards of Directors for both
academic and industry trade organizations, including the Chagas
Disease Foundation, and the College of Life Sciences Research
Foundation at North Carolina State University. He is also a
Director for Islet Sciences.
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com) is a global
biotechnology company advancing personalized medicine in
cardiology, oncology, and inherited diseases. The Company has three
complementary business units: Patient Testing, Biomarker
Identification, and Genetic Assays and Platforms, which provide
specialized diagnostic tests, contract research services for drug
development, and equipment, reagents and other consumables for
clinical and research applications in molecular testing and
cytogenetics.
Forward-Looking
Statements
Certain statements in this press release constitute
“forward-looking statements” of Transgenomic within the meaning of
the Private Securities Litigation Reform Act of 1995, which involve
known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future
results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited
to, those with respect to management's current views and estimates
of future economic circumstances, industry conditions, company
performance and financial results, including the ability of the
Company to grow its involvement in the diagnostic products and
services markets. The known risks, uncertainties and other factors
affecting these forward-looking statements are described from time
to time in Transgenomic's filings with the Securities and Exchange
Commission. Any change in such factors, risks and uncertainties may
cause the actual results, events and performance to differ
materially from those referred to in such statements. Accordingly,
the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995 with respect to all statements
contained in this press release. All information in this press
release is as of the date of the release and Transgenomic does not
undertake any duty to update this information, including any
forward-looking statements, unless required by law.
Investor Contact:Argot PartnersDavid Pitts,
212-600-1902david@argotpartners.comorCompany
Contact:Transgenomic, Inc.Donna Christian,
402-452-5416investorrelations@transgenomic.com
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precipio (NASDAQ:PRPO)
Historical Stock Chart
From Sep 2023 to Sep 2024